NewAmsterdam Pharma Co N.V.
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
NAMS$19.18+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| For the nine months ended September 30, | ||
|---|---|---|
| 2026 | 2025 | |
| (In thousands of USD) | ||
| Operating activities: | ||
| Loss for the period | (129,965) | (128,896) |
| Non-cash adjustments to reconcile loss for the period to net cash flows: | ||
| Depreciation and amortization | 188 | 161 |
| Non-cash rent expense | (11) | 3 |
| Fair value change - derivative earnout and warrants | (24,505) | 3,448 |
| Loss on disposal of property, plant and equipment | 18 | 1 |
| Foreign exchange (gains)/losses | 2,438 | (13,137) |
| Amortization of premium/discount on available-for-sale debt securities | (43) | (1,381) |
| Share-based compensation | 48,899 | 45,402 |
| Changes in working capital: | ||
| Changes in prepayments and other receivables | (4,052) | (3,216) |
| Changes in accounts payable | (4,315) | (409) |
| Changes in accrued expenses and other current liabilities | 38 | (2,876) |
| Changes in deferred revenue | 1,719 | (6,008) |
| Net cash used in operating activities | (109,591) | (106,908) |
| Investing activities: | ||
| Purchase of property, plant and equipment, including internal use software | (295) | (146) |
| Maturities of marketable securities | 144,390 | 71,563 |
| Purchases of marketable securities | (126,667) | (225,192) |
| Net cash provided by/(used in) investing activities | 17,428 | (153,775) |
| Financing activities: | ||
| Transaction costs on December 2024 issue of Ordinary Shares and Pre-Funded Warrants | — | (1,586) |
| Proceeds from exercise of warrants | 799 | 458 |
| Proceeds from exercise of options | 26,758 | 16,964 |
| Net cash provided by financing activities | 27,557 | 15,836 |
| Net change in cash, cash equivalents and restricted cash | (64,606) | (244,847) |
| Foreign exchange differences | (2,092) | 12,819 |
| Cash, cash equivalents and restricted cash at the beginning of the period | 491,323 | 771,743 |
| Cash, cash equivalents and restricted cash at the end of the period | 424,625 | 539,715 |
| Noncash financing and investing activities | ||
| Issuance of earnout shares | — | 40,807 |
| Reconciliation of cash, cash equivalents and restricted cash to the Condensed Consolidated Balance Sheets | ||
| Cash and cash equivalents | 423,129 | 538,407 |
| Restricted cash | 1,496 | 1,308 |
| 424,625 | 539,715 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.